

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Henlius Biotech, Inc.**

**上海復宏漢霖生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2696)**

**POLL RESULTS OF THE RESOLUTIONS PROPOSED AT  
THE 2022 FIRST EXTRAORDINARY GENERAL MEETING  
HELD ON THURSDAY, 28 JULY 2022**

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Henlius Biotech, Inc. (the “**Company**”) is pleased to announce the poll results of the 2022 first extraordinary general meeting (the “**EGM**”) held at Conference Room, 5th Floor, Innov Tower (Capitaland Building), Section A, 1801 Hongmei Road, Shanghai, PRC at 11:00 a.m. on Thursday, 28 July 2022.

References are made to the notice and the circular (the “**Circular**”) of the Company both dated 11 July 2022 in relation to the EGM. Unless the context otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

**EGM**

As at the date of the EGM, the total number of the issued shares of the Company (the “**Shares**”) was 543,494,853 Shares, comprising 364,189,618 domestic Shares, 15,876,694 unlisted foreign Shares and 163,428,541 H Shares, all of which entitled the holders (or authorised representatives) to attend and vote on the resolutions proposed at the EGM (the “**Resolutions**”). Shareholders or authorised representatives holding an aggregate of 353,638,316 Shares with voting rights, representing approximately 65.067464% of the total number of the Shares with voting rights of the Company were present at the EGM. All Directors attended the EGM.

To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, no Shareholder was required to abstain from voting on any of the Resolutions under the Listing Rules. There was no Share entitling the holder to attend the EGM and abstain from voting in favour of any of the Resolutions under Rule 13.40 of the Listing Rules. No Shareholder has stated the intention in the Circular to vote against or to abstain from voting on any of the Resolutions.

Pursuant to Listing Rules and the articles of association of the Company (the “**Articles of Association**”), Computershare Hong Kong Investor Services Limited, representatives from the Shareholders and a member of the board of supervisors of the Company acted as the scrutineers for vote-tabulation at the EGM.

The EGM was convened in compliance with the requirements of the Company Law of PRC and the Articles of Association. Mr. Wenjie Zhang, chairman of the Board of the Company, acted as the chairman of the EGM.

## POLL RESULTS OF THE EGM

Resolutions proposed at the EGM were voted by way of poll, the results of which are as follows:

Ordinary Resolutions		Number of valid votes and percentage of total number of votes (%)		
		For	Against	Abstain
1.	To consider and approve the resolutions in relation to the re-appointment and appointment of directors of the third session of the board of directors of the Company	/		
1.1	the re-appointment of Mr. Wenjie Zhang as an executive director of the Company	353,617,216 (99.994033%)	21,100 (0.005967%)	0 (0.000000%)
1.2	the re-appointment of Mr. Qiyu Chen as a non-executive director of the Company	353,449,671 (99.946656%)	188,645 (0.053344%)	0 (0.000000%)
1.3	the re-appointment of Mr. Yifang Wu as a non-executive director of the Company	353,606,371 (99.990967%)	31,945 (0.009033%)	0 (0.000000%)
1.4	the re-appointment of Ms. Xiaohui Guan as a non-executive director of the Company	353,606,371 (99.990967%)	31,945 (0.009033%)	0 (0.000000%)
1.5	the appointment of Mr. Deyong Wen as a non-executive director of the Company	353,528,671 (99.968995%)	109,645 (0.031005%)	0 (0.000000%)
1.6	the re-appointment of Mr. Zihou Yan as a non-executive director of the Company	353,638,316 (100.000000%)	0 (0.000000%)	0 (0.000000%)
1.7	the re-appointment of Mr. Tak Young So as an independent non-executive director of the Company	353,638,316 (100.000000%)	0 (0.000000%)	0 (0.000000%)
1.8	the re-appointment of Dr. Lik Yuen Chan as an independent non-executive director of the Company	353,638,316 (100.000000%)	0 (0.000000%)	0 (0.000000%)
1.9	the re-appointment of Dr. Guoping Zhao as an independent non-executive director of the Company	353,638,316 (100.000000%)	0 (0.000000%)	0 (0.000000%)
1.10	the re-appointment of Dr. Ruilin Song as an independent non-executive director of the Company	353,449,671 (99.946656%)	188,645 (0.053344%)	0 (0.000000%)
As more than half of the votes were cast in favour of resolutions 1.1 to 1.10, such resolutions were duly passed as ordinary resolutions.				

Ordinary Resolutions		Number of valid votes and percentage of total number of votes (%)		
		For	Against	Abstain
2.	To consider and approve the resolutions in relation to the re-appointment of shareholder representative supervisors of the third session of the board of supervisors of the Company	/		
2.1	the re-appointment of Ms. Rongli Feng as a shareholder representative supervisor of the Company	353,634,916 (99.999039%)	0 (0.000000%)	3,400 (0.000961%)
2.2	the re-appointment of Mr. Deli Kong as a shareholder representative supervisor of the Company	353,613,816 (99.993072%)	21,100 (0.005967%)	3,400 (0.000961%)
As more than half of the votes were cast in favour of resolutions 2.1 to 2.2, such resolutions were duly passed as ordinary resolutions.				

On behalf of the Board  
**Shanghai Henlius Biotech, Inc.**  
**Wenjie Zhang**  
*Chairman*

Hong Kong, 28 July 2022

*As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as chairman and the executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.*